
Opinion|Videos|January 24, 2025
Academic Perspectives on Health-Related Quality of Life From COMMANDS at ASH 2024
Author(s)Thomas W. LeBlanc, MD, MA
Thomas W. LeBlanc, MD, MA, discusses how treatment regimens for low-risk myelodysplastic syndromes (LR-MDS) significantly impact health-related quality of life (HRQOL), with data from the COMMANDS study (Oliva et al, ASH 2024, Abstract 3216) highlighting the correlation between HRQOL and clinical end points, and explore how incorporating HRQOL data into clinical decision-making can guide more patient-centered treatment choices in community settings.
Advertisement
Episodes in this series

Video content above is prompted by the following:
How do treatment regimens impact HRQOL in LR-MDS?
- Please review and discuss HRQOL from COMMANDS: Oliva et al, ASH 2024, Abstract 3216.
- How do HRQOL data correlate with clinical end points?
- How can HRQOL data impact treatment choices in the community?
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
2
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
3
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5































